Remove tag go-therapeutics
article thumbnail

Grand Rounds April 14, 2023: RECOVER in Action – Status of Clinical Trial Protocols (Kanecia Zimmerman, PhD, MD, MPH)

Rethinking Clinical Trials

This broad set of clinical conditions and varied underlying causes underscore the need for testing a broad portfolio of therapeutic agents. While the pandemic is transitioning from pandemic to endemic state, do you see any signs that PASC will go away? No, there are no signs PASC is going away.

article thumbnail

Statement on Omicron sublineage BA.2

The Pharma Data

As part of its on-going work to track variants, WHO’s Technical Advisory Group on SARS-CoV-2 Virus Evolution ( TAG-VE ) met yesterday to discuss the latest evidence on the Omicron variant of concern, including its sublineages BA.1 Reinfection with BA.2 2 following infection with BA.1 WHO will continue to closely monitor the BA.2

Protein 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds October 21, 2022: Disinformation, Cyberthreat, and Choice: Protecting Patients and Clinical Research From the Digital Triple Threat (Eric Perakslis, PhD; Andrea Downing)

Rethinking Clinical Trials

The questions are how are you going to play online and how are you going to conduct your research in a way that is most effective and will keep everyone safe? Should social media for teenagers be regulated like a digital therapeutic, given how addictive they are and the behavior modification. Case study: The U.K.

article thumbnail

Q&A: A decade on, what’s next for CAR-T therapies?

Pharmaceutical Technology

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. This includes the first potential approval of a CRISPR-based gene therapy called exa-cel , which is developed by CRISPR Therapeutics and Vertex Pharmaceuticals. At the end of last year, we had 2,800.

article thumbnail

Pear claims breakthrough tag for alcohol use disorder DTx

pharmaphorum

Digital health company Pear Therapeutics has won FDA breakthrough device status for reSET-A, its development-stage prescription digital therapeutic (DTx) for people with alcohol-use disorder. The post Pear claims breakthrough tag for alcohol use disorder DTx appeared first on. Photo by thom masat on Unsplash.

article thumbnail

Grand Rounds March 24, 2023: From Observational Studies to Pragmatic Clinical Trials: (Almost) A Decade of Research in PCORnet® (Erin Holve, PhD, MPH, MPP; Russell Rothman, MD, MPP; Schuyler Jones, MD; Neha Pagidipati, MD, MPH)

Rethinking Clinical Trials

across all therapeutic areas. There are still some discussions now about where we might go with the common data model and if there are efficiencies in supporting more than one data model. Every PCORnet®. Many different types of observational studies are possible with PCORnet®. For now, PCORnet®.has

article thumbnail

Biogen’s Aduhelm rollout goes from bad to worse

pharmaphorum

Analysts were predicting sales of Biogen’s recently approved Alzheimer’s therapy Aduhelm may start to gather a little momentum in the third quarter, but the drug seems to be going into reverse. Vounatsos also insisted that Aduhelm’s price tag has not been a factor discouraging treatment with the drug.

Sales 121